Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML

Jianfang Zeng, MD PhD, Alice Soragni, PhD, Jo Ishizawa, MDPhD, Vivian Ruvolo, MS, Christopher B. Benton, MD, Teresa McQueen, MS, Peter Ruvolo, PhD, Yuan Qi, PhD, Xiaoping Su, PhD, Jared Burks, PhD, David S. Eisenberg, PhD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 3944.

https://doi.org/10.1182/blood.V128.22.3944.3944

Published: 2016

Journal Articles

NEOD001 Specifically Binds Aggregated Light Chain Infiltrates in Multiple Organs from Patients with AL Amyloidosis and Promotes Phagocytic Clearance of AL Aggregates in Vitro

Wagner Zago, Mark Renz, Ronald Torres, Philip J. Dolan, Robin M. Barbour, Joshua R. Salmans, Paul J. Shughrue, Dale Schenk, Gene G. Kinney

Blood (2015) 126 (23): 3016.

https://doi.org/10.1182/blood.V126.23.3016.3016

Published: 2015

Journal Articles

Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs

Ibrahim El Serafi, MD PhD, Manuchehr Abedi-Valugerdi, PhD, Seán Naughton, Maryam Saghafian, DVM, PhD, Jonas Mattsson, MD PhD, Ali Moshfegh, PhD, Ylva Terelius, PhD, Zuzana Potacova, MDPhD, Moustapha Hassan, PhD

Blood (2014) 124 (21): 1150.

https://doi.org/10.1182/blood.V124.21.1150.1150

Published: 2014

Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 2959.

https://doi.org/10.1182/blood.V120.21.2959.2959

Published: 2012

Journal Articles

Splenic Rupture as a Complication of Autologous Hematopoietic Cell Transplantation In a Patient with Systemic Amyloidosis.

Taiga Nishihori, MD, Noman Ashraf, MD, Estrella M. Carballido, MD, Timothy Yeatman, M.D., Lynn C. Moscinski, MD, Melissa Alsina, MD

Blood (2010) 116 (21): 4528.

https://doi.org/10.1182/blood.V116.21.4528.4528

Published: 2010

NARROW

Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML

NEOD001 Specifically Binds Aggregated Light Chain Infiltrates in Multiple Organs from Patients with AL Amyloidosis and Promotes Phagocytic Clearance of AL Aggregates in Vitro

Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Splenic Rupture as a Complication of Autologous Hematopoietic Cell Transplantation In a Patient with Systemic Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML

NEOD001 Specifically Binds Aggregated Light Chain Infiltrates in Multiple Organs from Patients with AL Amyloidosis and Promotes Phagocytic Clearance of AL Aggregates in Vitro

Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Splenic Rupture as a Complication of Autologous Hematopoietic Cell Transplantation In a Patient with Systemic Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only